{"organizations": [], "uuid": "72b528ed23de5bee27fa21b1ce214d17c9267981", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-insmed-announces-fda-acceptance-fo/brief-insmed-announces-fda-acceptance-for-filing-of-nda-for-lung-disease-treatment-idUSASC0A2L6", "country": "US", "domain_rank": 408, "title": "BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.945, "site_type": "news", "published": "2018-05-16T20:16:00.000+03:00", "replies_count": 0, "uuid": "72b528ed23de5bee27fa21b1ce214d17c9267981"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-insmed-announces-fda-acceptance-fo/brief-insmed-announces-fda-acceptance-for-filing-of-nda-for-lung-disease-treatment-idUSASC0A2L6", "ord_in_thread": 0, "title": "BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment", "locations": [], "entities": {"persons": [], "locations": [{"name": "insmed", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "insmed inc", "sentiment": "negative"}, {"name": "fda acceptance for filing of nda", "sentiment": "negative"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "mac", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Insmed Inc:\n* INSMED ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC\n* INSMED INC - PDUFA ACTION DATE SET FOR SEPTEMBER 28, 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T20:16:00.000+03:00", "crawled": "2018-05-17T14:24:23.000+03:00", "highlightTitle": ""}